Latigo Biotherapeutics

Latigo Biotherapeutics is a clinical-stage biotechnology company developing innovative non-opioid pain medicines that target the source of pain. Their lead candidate, LTG-001, is an oral, selective Nav1.8 inhibitor for acute pain, and LTG-305 is an oral, selective Nav1.8 inhibitor in Phase 1 clinical trials for chronic pain. Latigo aims to provide effective, rapid-acting pain relief without the risk of addiction.

Funding Round: Series B

Funding Amount: $150M

Date: 17-Mar-2025

Investors: Blue Owl Capital, Deep Track Capital, Access Biotechnology, Qatar Investment Authority, Cormorant Asset Management, Sanofi Ventures, Rock Springs Capital, UPMC Enterprises, Kern Capital, Westlake Village BioPartners, Foresite Capital, 5AM Ventures, Alexandria Venture Investments

Markets: Biotech, Pharmaceuticals, Healthtech

HQ: Thousand Oaks, California, United States

Founded: 2018

Website: https://www.latigobio.com/

LinkedIn: https://www.linkedin.com/company/latigobio/

Twitter:

Instagram:

Facebook:

Crunchbase: https://www.crunchbase.com/organization/latigo-biotherapeutics

Pitchbook: https://pitchbook.com/profiles/company/466121-80